# Acorda Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acorda-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.acorda.com
- Total disclosed funding: $89M
- Latest round: Series C (May 9, 2003)
- Investors on record: 12

## About

Acorda Therapeutics, Inc. focuses on developing and commercializing innovative therapies aimed at improving the quality of life for patients with neurological diseases.Acorda Therapeutics, Inc. specializes in therapies for neurological disorders. Founded in 1995 in the U.S., the company has undergone various strategic developments over the years. The current CEO is Ron Cohen. Acorda's significant milestone includes raising USD 31.50 mn through a PIPE funding round, which represents the total amount raised by the firm. The most recent deal occurred on February 1, 2011, following a previous listing that raised USD 33 mn in 2006.Acorda Therapeutics Inc. specializes in developing and commercializing innovative therapies for neurological diseases. Their core offerings include AMPYRA® (dalfampridine), a treatment designed to improve walking in patients with multiple sclerosis, and INBRIJA® (levodopa inhalation powder), utilized for managing off periods in patients with Parkinson's disease. These products aim to alleviate symptoms and enhance the quality of life for individuals facing challenges from these neurological conditions. Additionally, Acorda has developed ARCUS® technology, facilitating effective medication delivery and primarily markets its products in North America and select European regions.Acorda Therapeutics generated revenue of USD 117.63 mn in 2023. The company's revenue is driven by the sale of its pharmaceutical products, particularly AMPYRA® and INBRIJA®. Transactions typically involve wholesalers purchasing the products at wholesale prices, which are subsequently sold to healthcare providers and pharmacies, ensuring access for end users. The pricing strategy reflects the innovative nature and clinical benefits of these therapies, maintaining a viable economic model for the business.Acorda Therapeutics plans to leverage recent funding to support the development of new products and expand into new geographic markets. The company is focusing on upcoming therapies and is targeting regions that include Europe and specific markets in North America. The funding raised in the PIPE round will be utilized to advance their product pipeline and support market-entry strategies, following a notable deal in February 2006 where they raised USD 33 mn.

## Funding rounds

- Series C, May 9, 2003, $55M — AAC Capital Partners, Forward Ventures, TVM Capital Life Science, Easton Capital Investment Group, JP Morgan Asset Management, Cross Atlantic Partners, MPM BioImpact
- Series A, Jan 8, 2001, $34M — Forward Ventures, RBC Capital Markets, CDIB Capital Group, Swiss Life Asset Management, Novartis Venture Fund, BayStar Capital

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series C
- RBC Capital Markets (https://capitalatlas.ai/funds/rbc-capital-markets) — Series A
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series A
- Swiss Life Asset Management — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- BayStar Capital (https://capitalatlas.ai/funds/baystar-capital) — Series A
- AAC Capital Partners (https://capitalatlas.ai/funds/aac-capital-partners) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series C
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series C
- Cross Atlantic Partners (https://capitalatlas.ai/funds/cross-atlantic-partners) — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C